.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers have achieved a breakthrough in liver-targeted mRNA delivery by developing a novel immune-modulating nanodrug. This innovation addresses a significant hurdle in genetic medicine. Currently, inflammation often hampers the success of mRNA-based therapies. Specifically, inflammatory states trigger a self-defensive response in hepatocytes. This mechanism downregulates global protein synthesis to block potential viral threats. However, it also significantly reduces the efficiency of therapeutic mRNA delivered via lipid nanoparticles (LNPs).
Furthermore, the team introduced a telodendrimer (TD) nanodrug (ND) to modulate the immune environment. They tested this technology in both human and mouse immune cells. Additionally, the researchers evaluated its effects on primary human hepatocytes (PHH). The results were impressive. The TD ND successfully inhibited endotoxin-induced inflammation. Consequently, this led to improved cell proliferation and significantly higher mRNA uptake in human monocytes and liver cells.
Moreover, the findings demonstrated that TD ND is superior to conventional steroid drugs. While steroids are common, they can sometimes impair liver recovery. In contrast, the TD ND sustained liver function in mice while rebooting the efficacy of liver-targeted mRNA delivery. Therefore, this adjuvant therapy offers a promising path for treating inflammatory liver diseases.
Inflammation acts as a biological barrier. It triggers a cellular defense that reduces mRNA expression, which prevents therapeutic genes from being translated into functional proteins.
The TD nanodrug acts as an immune modulator. It inhibits the inflammatory response that normally blocks mRNA expression, thereby enhancing the overall delivery efficiency and liver function.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new telodendrimer nanodrug improves liver-targeted mRNA delivery by suppressing inflammation and outperforming traditional steroids in preclinical studies...
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
